New cancer Drug's hidden impact on cough medicine revealed

NCT ID NCT07241065

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how a cancer drug called capivasertib changes the way the body processes dextromethorphan, a common cough suppressant. Researchers will give 42 healthy adults dextromethorphan alone and then with capivasertib to measure drug levels in the blood. The goal is to understand potential drug interactions for safer use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

capivasertib and dextromethorphan

What this could lead to

If successful, this study could help doctors understand how capivasertib interacts with other drugs, leading to safer dosing guidelines.

What could go wrong

This is an early-stage, small study in healthy people, not patients. Results may not predict effects in sick individuals or lead directly to new treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Berlin, 14050, Germany